journal
MENU ▼
Read by QxMD icon Read
search

Neurology and Therapy

journal
https://read.qxmd.com/read/30706431/real-world-characterization-of-dimethyl-fumarate-related-gastrointestinal-events-in-multiple-sclerosis-management-strategies-to-improve-persistence-on-treatment-and-patient-outcomes
#1
Jinny Min, Stanley Cohan, Enrique Alvarez, Jacob Sloane, J Theodore Phillips, Anneke van der Walt, Irene Koulinska, Fang Fang, Catherine Miller, Andrew Chan
INTRODUCTION: Delayed-release dimethyl fumarate (DMF) is an effective treatment for multiple sclerosis (MS). Some patients experience gastrointestinal (GI) adverse events (AEs) that may lead to premature DMF discontinuation. This study characterized the impact of site-specific GI management strategies on the occurrence of GI events and discontinuation patterns. METHODS: Data on GI events and DMF persistence were retrospectively abstracted from medical records of patients treated with DMF in routine medical practice in the EFFECT study (NCT02776072)...
January 31, 2019: Neurology and Therapy
https://read.qxmd.com/read/30701476/neurology-and-therapy-looking-back-on-2018-and-forward-to-2019
#2
LETTER
Marwan Sabbagh, Antonio Bertolotto
No abstract text is available yet for this article.
January 30, 2019: Neurology and Therapy
https://read.qxmd.com/read/30661227/intravenous-milrinone-salvage-therapy-in-acute-internal-carotid-artery-occlusion-case-report
#3
Hosam Al-Jehani, Mark Angle
INTRODUCTION: Acute internal carotid artery occlusion is a devastating form of ischemic accident with significant morbidity and possible mortality. The "threatened hemisphere" is allowed limited access to collateral circulation further worsening the ischemic burden and the overall prognosis. METHODS: We present the details of a case of a 38-year-old woman who suffered from an ischemic stroke. The clinical course of which showed a hemodynamic dependence to preserve her neurological function, prompting the use of the phosphodiesterase inhibitor milrinone to maintain her neurological function...
January 19, 2019: Neurology and Therapy
https://read.qxmd.com/read/30617838/the-treatment-of-hypersalivation-in-rett-syndrome-with-botulinum-toxin-efficacy-and-clinical-implications
#4
Pia Bernardo, Enza Raiano, Gerarda Cappuccio, Raffaele Dubbioso, Carmela Bravaccio, Emilia Vergara, Silvio Peluso, Fiore Manganelli, Marcello Esposito
INTRODUCTION: Subjects with Rett syndrome (RS) develop invariably severe motor deterioration resulting in swallowing difficulties that may produce excessive drooling. Hypersalivation can cause discomfort due to hygienic problems and may complicate with oral and respiratory dysfunctions. The aim of this study is to evaluate the response to treatment with botulinum toxin (BTX) for hypersalivation and to identify possible benefits of saliva reduction on oral motor and respiratory disorders of patients with RS...
January 8, 2019: Neurology and Therapy
https://read.qxmd.com/read/30565050/treatment-patterns-healthcare-resource-utilization-and-costs-among-medicare-patients-with-multiple-sclerosis-in-relation-to-disease-modifying-therapy-and-corticosteroid-treatment
#5
Marie Sanchirico, Amanda Caldwell-Tarr, Pallavi Mudumby, Lobat Hashemi, Robert Dufour
INTRODUCTION: Despite the increasing age of the multiple sclerosis (MS) patient population, data are lacking on MS patients in later life. This retrospective study investigated treatment patterns, healthcare resource utilization (HCRU), and healthcare costs (HCCs) for patients enrolled in Medicare, in relation to disease-modifying therapy (DMT) and corticosteroid treatment as a marker for relapse. METHODS: Medical and pharmacy claims between January 1, 2010 and July 31, 2015 identified MS patients...
December 18, 2018: Neurology and Therapy
https://read.qxmd.com/read/30539376/emerging-immunotherapies-for-parkinson-disease
#6
REVIEW
Samis M A Zella, Judith Metzdorf, Emine Ciftci, Friederike Ostendorf, Siegfried Muhlack, Ralf Gold, Lars Tönges
Symptomatic treatment options for Parkinson disease have steadily improved, and individualized therapeutic approaches are becoming established for every stage of the disease. However, disease-modifying therapy with a causal approach is still unavailable. The central causative role of alpha-synuclein pathology, including its progressive spread to most areas of the CNS, has been widely recognized, and a strong involvement of immune responses has recently been discovered. New immunologic technologies have been shown to effectively prevent the progression of alpha-synuclein pathology in animal models...
December 11, 2018: Neurology and Therapy
https://read.qxmd.com/read/30506485/granulocyte-macrophage-colony-stimulating-factor-as-a-therapeutic-target-in-multiple-sclerosis
#7
REVIEW
Jehan Aram, Anna Francis, Radu Tanasescu, Cris S Constantinescu
Multiple sclerosis is an inflammatory neurodegenerative disease of the central nervous system (CNS) and the most frequent cause of non-traumatic disability in adults in the Western world. Currently, several drugs have been approved for the treatment of multiple sclerosis. While the newer drugs are more effective, they have less favourable safety profiles. Thus, there is a need to identify new targets for effective and safe therapies, particularly in patients with progressive disease for whom no treatments are available...
December 1, 2018: Neurology and Therapy
https://read.qxmd.com/read/30506301/a-videogame-based-digital-therapeutic-to-improve-processing-speed-in-people-with-multiple-sclerosis-a-feasibility-study
#8
Riley M Bove, Gillian Rush, Chao Zhao, William Rowles, Priya Garcha, John Morrissey, Adrian Schembri, Titi Alailima, Dawn Langdon, Katherine Possin, Adam Gazzaley, Anthony Feinstein, Joaquin Anguera
INTRODUCTION: Self-administered in-home digital therapeutics could expand access to cognitive rehabilitation for individuals with multiple sclerosis (MS), over half of whom experience cognitive impairment (CI). However, feasibility in an MS population must be clarified. This study was conducted to assess the feasibility of deploying a videogame-like digital treatment for CI in MS, including initial efficacy and barriers to adherence. METHODS: In this pilot study, 21 participants with MS completed an in-clinic baseline neurological evaluation...
November 30, 2018: Neurology and Therapy
https://read.qxmd.com/read/30484080/acknowledgement-to-authors-referees-and-readers
#9
Marwan N Sabbagh, Antonio Bertolotto
No abstract text is available yet for this article.
November 27, 2018: Neurology and Therapy
https://read.qxmd.com/read/30414084/patient-power-revolution-in-multiple-sclerosis-navigating-the-new-frontier
#10
David Yeandle, Peter Rieckmann, Gavin Giovannoni, Nektaria Alexandri, Dawn Langdon
A debate on shared decision making in multiple sclerosis (MS) was led by a patient advocate and leading neurologists from the MS in the 21st Century Steering Group. Key themes and salient points which emerged from the debate and audience discussions are reported in this article. Arguments against shared decision making included the fact that physicians study and practice for years to reach their level of expertise, and that the level of understanding required to make these decisions may not be possible to communicate to patients within time-limited consultations...
December 2018: Neurology and Therapy
https://read.qxmd.com/read/30361858/phase-1-parkinson-s-disease-studies-show-the-dopamine-d1-d5-agonist-pf-06649751-is-safe-and-well-tolerated
#11
U Shivraj Sohur, David L Gray, Sridhar Duvvuri, Yao Zhang, Kathleen Thayer, Gang Feng
INTRODUCTION: There is a need for new therapies in Parkinson's disease that may help to address known limitations of current options. PF-06649751 is a novel, highly selective dopamine D1/D5 agonist targeted for Parkinson's disease treatment. METHODS: The safety, pharmacokinetics, and pharmacodynamics of PF-06649751 were assessed in single ascending dose and multiple ascending dose clinical trials in patients with Parkinson's disease. The single ascending dose study (N = 18) was a double-blind, placebo-controlled study with a three-way crossover design consisting of three treatment periods separated by 7-day study drug washout periods...
December 2018: Neurology and Therapy
https://read.qxmd.com/read/30293098/burden-of-migraine-in-europe-using-self-reported-digital-diary-data-from-the-migraine-buddy%C3%A2-application
#12
Pamela Vo, Nicolas Paris, Aikaterini Bilitou, Tomas Valena, Juanzhi Fang, Christel Naujoks, Ann Cameron, Frederic de Reydet de Vulpillieres, Francois Cadiou
INTRODUCTION: Migraine is a neurological disease characterized by recurring attacks that can cause severe disabling pain. This study described the burden of migraine as reported by individuals with migraine in the real world using a mobile application. METHODS: A retrospective, cross-sectional analysis was conducted using data captured through the Migraine Buddy© smartphone application from adult, self-diagnosed individuals with migraine in 17 European countries...
December 2018: Neurology and Therapy
https://read.qxmd.com/read/30027457/antipsychotic-related-movement-disorders-drug-induced-parkinsonism-vs-tardive-dyskinesia-key-differences-in-pathophysiology-and-clinical-management
#13
REVIEW
Kristen M Ward, Leslie Citrome
INTRODUCTION: Drug-induced parkinsonism (DIP) and tardive dyskinesia (TD) are stigmatizing movement disorders associated with exposure to dopamine receptor blocking agents such as antipsychotics, but they differ in their pathophysiology and clinical management. Treatment for one may worsen the other, and there are important diagnostic clues that assist in making an accurate assessment and instituting a rational treatment plan. METHODS: A literature review was executed to identify articles relating to the presentation, pathophysiology, epidemiology, and management of DIP and TD...
December 2018: Neurology and Therapy
https://read.qxmd.com/read/30415358/authors-response-to-the-letter-to-the-editor-regarding-a-comprehensive-review-on-copemyl-%C3%A2
#14
LETTER
Pietro Annovazzi, Antonio Bertolotto, Vincenzo Brescia Morra, Claudio Gasperini, Enrico Montanari, Pierluigi Navarra, Francesco Patti, Maria Pia Sormani, Angelo Ghezzi
No abstract text is available yet for this article.
November 10, 2018: Neurology and Therapy
https://read.qxmd.com/read/30415357/patient-and-physician-perspectives-in-a-case-of-severe-traumatic-brain-injury
#15
Rhoderick M Casis
Traumatic brain injury is a challenge for general practitioners and specialists worldwide due to the heterogeneous clinical picture, secondary injuries and complex treatment including surgery, medication, intensive care, nutrition and rehabilitation. This case report is about a TBI patient with a score of four on the Glasgow Coma Scale when she was transferred from the primary hospital to our center. Her condition, treatment options and expectations were discussed with the relatives. The patient was subjected to surgery and received pharmacologic intervention including a neurotrophic drug and extensive rehabilitation measures including occupational therapy...
November 10, 2018: Neurology and Therapy
https://read.qxmd.com/read/30415356/letter-to-the-editor-regarding-a-comprehensive-review-on-copemyl-%C3%A2
#16
LETTER
Giancarlo Comi, Ferdinando Nicoletti, Pier Luigi Canonico, Diego Centonze
No abstract text is available yet for this article.
November 10, 2018: Neurology and Therapy
https://read.qxmd.com/read/30315481/european-and-american-guidelines-for-multiple-sclerosis-treatment
#17
Angelo Ghezzi
The management and treatment of multiple sclerosis (MS) is becoming more and more complex as many medications are now available, with different routes of administration, mechanisms of action, and effectiveness and safety profiles. The decision-making process to choose the right medication is a complex task requiring a careful evaluation of the results of clinical and post-marketing studies, and the capability to translate data from clinical studies to patients in everyday clinical practice. Two European neurological societies, the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and European Academy of Neurology (EAN), and the American Academy of Neurology (AAN) have recently delivered guidelines for MS treatment, helping neurologists to address the most common clinical issues related to this topic...
October 12, 2018: Neurology and Therapy
https://read.qxmd.com/read/30255467/decreased-behavioral-abnormalities-after-treatment-with-combined-donepezil-and-yokukansankachimpihange-in-alzheimer-disease-an-observational-study-the-osaki-tajiri-project
#18
Kenichi Meguro, Satoshi Yamaguchi
INTRODUCTION: Yokukansan is one of the traditional herbal medicines (Kampo medicine in Japan) commonly used in the treatment of the Behavioral and Psychological Symptoms of Dementia (BPSD). We performed an observational study using yokukansankachimpihange, which contains a nobiletin-rich Citrus reticulata, to determine whether it could improve BPSD as well as cognitive impairment in patients with Alzheimer disease (NINCDS-ADRDA). METHODS: Forty-six (23 vs. 23) patients were enrolled in the study sample (donepezil group vs...
September 25, 2018: Neurology and Therapy
https://read.qxmd.com/read/30251237/dibenzazepine-agents-in-epilepsy-how-does-eslicarbazepine-acetate-differ
#19
Charlotte Lawthom, Jukka Peltola, Rob McMurray, Emma Dodd, Vicente Villanueva
Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL) belong to the dibenzazepine family of antiepileptic drugs and are all thought to primarily act as sodium channel blockers (SCBs). However, ESL is structurally distinct from CBZ and OXC, resulting in differences in metabolism, pharmacokinetics, and pharmacodynamics. Despite a lack of direct comparative data, evidence for potential differences in effectiveness and tolerability within the dibenzazepine family has emerged from studies in which patients being treated with one dibenzazepine agent have received adjunctive treatment with another (having achieved insufficient seizure control with the first) or have transitioned from one dibenzazepine agent to another because of lack of effectiveness or poor tolerability...
September 24, 2018: Neurology and Therapy
https://read.qxmd.com/read/30167914/practical-evidence-based-recommendations-for-patients-with-multiple-sclerosis-who-want-to-have-children
#20
REVIEW
Yara Dadalti Fragoso, Tarso Adoni, Joseph B Bidin Brooks, Alessandro Finkelsztejn, Paulo Diniz da Gama, Anderson K Grzesiuk, Vanessa Daccach Marques, Monica Fiuza K Parolin, Henry K Sato, Daniel Lima Varela, Claudia Cristina F Vasconcelos
Multiple sclerosis (MS) management presently aims to reach a state of no (or minimal) evidence of disease activity. The development and commercialization of new drugs has led to a renewed interest in family planning, since patients with MS may face a future with reduced (or no) disease-related neurological disability. The advice of neurologists is often sought by patients who want to have children and need to know more about disease control at conception and during pregnancy and the puerperium. When MS is well controlled, the simple withdrawal of drugs for patients who intend to conceive is not an option...
August 30, 2018: Neurology and Therapy
journal
journal
49896
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"